Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100

Rebecca M. Shepherd, Benjamin J. Capoccia, Steven M. Devine, John DiPersio, Kathryn M. Trinkaus, David Ingram, Daniel C. Link

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Circulating endothelial progenitor cells (EPCs) are thought to contribute to angiogenesis following vascular injury, stimulating interest in their ability to mediate therapeutic angiogenesis. However, the number of EPCs in the blood is low, limiting endogenous repair, and a method to rapidly mobilize EPCs has not been reported. In this study, healthy donors were mobilized sequentially with the CXCR4 antagonist, AMD3100, and G-CSF. The number of EPCs and circulating angiogenic cells (CACs) in the blood and pheresis product was determined and the angiogenic capacity of each cell population assessed. Compared with baseline, treatment with AMD3100 or G-CSF increased the number of blood CACs 10.0-fold ± 4.4-fold and 8.8-fold ± 3.7-fold, respectively. The number of EPCs in the blood increased 10.2-fold ± 3.3-fold and 21.8-fold ± 5.4-fold, respectively. On a percell basis, CACs harvested from G-CSF-mobilized blood displayed increased in vivo angiogenic potential compared with AMD3100-mobilized CACs. Mobilized EPCs displayed a greater proliferative capacity than EPCs isolated from baseline blood. Both CACs and EPCs were efficiently harvested by leukapheresis. Cryopreserved CACs but not EPCs retained functional activity after thawing. These data show that AMD3100 is a potent and rapid mobilizer of angiogenic cells and demonstrate the feasibility of obtaining and storing large numbers of angiogenic cells by leukapheresis.

Original languageEnglish (US)
Pages (from-to)3662-3667
Number of pages6
JournalBlood
Volume108
Issue number12
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Endothelial cells
Blood
Granulocyte Colony-Stimulating Factor
Leukapheresis
Therapeutics
JM 3100
Endothelial Progenitor Cells
Blood Component Removal
Thawing
Vascular System Injuries
Blood Cells
Repair
Cell Count
Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Shepherd, R. M., Capoccia, B. J., Devine, S. M., DiPersio, J., Trinkaus, K. M., Ingram, D., & Link, D. C. (2006). Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood, 108(12), 3662-3667. https://doi.org/10.1182/blood-2006-06-030577

Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. / Shepherd, Rebecca M.; Capoccia, Benjamin J.; Devine, Steven M.; DiPersio, John; Trinkaus, Kathryn M.; Ingram, David; Link, Daniel C.

In: Blood, Vol. 108, No. 12, 01.12.2006, p. 3662-3667.

Research output: Contribution to journalArticle

Shepherd, RM, Capoccia, BJ, Devine, SM, DiPersio, J, Trinkaus, KM, Ingram, D & Link, DC 2006, 'Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100', Blood, vol. 108, no. 12, pp. 3662-3667. https://doi.org/10.1182/blood-2006-06-030577
Shepherd, Rebecca M. ; Capoccia, Benjamin J. ; Devine, Steven M. ; DiPersio, John ; Trinkaus, Kathryn M. ; Ingram, David ; Link, Daniel C. / Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. In: Blood. 2006 ; Vol. 108, No. 12. pp. 3662-3667.
@article{13018ed0d2314c06aaf2d85b2db864af,
title = "Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100",
abstract = "Circulating endothelial progenitor cells (EPCs) are thought to contribute to angiogenesis following vascular injury, stimulating interest in their ability to mediate therapeutic angiogenesis. However, the number of EPCs in the blood is low, limiting endogenous repair, and a method to rapidly mobilize EPCs has not been reported. In this study, healthy donors were mobilized sequentially with the CXCR4 antagonist, AMD3100, and G-CSF. The number of EPCs and circulating angiogenic cells (CACs) in the blood and pheresis product was determined and the angiogenic capacity of each cell population assessed. Compared with baseline, treatment with AMD3100 or G-CSF increased the number of blood CACs 10.0-fold ± 4.4-fold and 8.8-fold ± 3.7-fold, respectively. The number of EPCs in the blood increased 10.2-fold ± 3.3-fold and 21.8-fold ± 5.4-fold, respectively. On a percell basis, CACs harvested from G-CSF-mobilized blood displayed increased in vivo angiogenic potential compared with AMD3100-mobilized CACs. Mobilized EPCs displayed a greater proliferative capacity than EPCs isolated from baseline blood. Both CACs and EPCs were efficiently harvested by leukapheresis. Cryopreserved CACs but not EPCs retained functional activity after thawing. These data show that AMD3100 is a potent and rapid mobilizer of angiogenic cells and demonstrate the feasibility of obtaining and storing large numbers of angiogenic cells by leukapheresis.",
author = "Shepherd, {Rebecca M.} and Capoccia, {Benjamin J.} and Devine, {Steven M.} and John DiPersio and Trinkaus, {Kathryn M.} and David Ingram and Link, {Daniel C.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1182/blood-2006-06-030577",
language = "English (US)",
volume = "108",
pages = "3662--3667",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100

AU - Shepherd, Rebecca M.

AU - Capoccia, Benjamin J.

AU - Devine, Steven M.

AU - DiPersio, John

AU - Trinkaus, Kathryn M.

AU - Ingram, David

AU - Link, Daniel C.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Circulating endothelial progenitor cells (EPCs) are thought to contribute to angiogenesis following vascular injury, stimulating interest in their ability to mediate therapeutic angiogenesis. However, the number of EPCs in the blood is low, limiting endogenous repair, and a method to rapidly mobilize EPCs has not been reported. In this study, healthy donors were mobilized sequentially with the CXCR4 antagonist, AMD3100, and G-CSF. The number of EPCs and circulating angiogenic cells (CACs) in the blood and pheresis product was determined and the angiogenic capacity of each cell population assessed. Compared with baseline, treatment with AMD3100 or G-CSF increased the number of blood CACs 10.0-fold ± 4.4-fold and 8.8-fold ± 3.7-fold, respectively. The number of EPCs in the blood increased 10.2-fold ± 3.3-fold and 21.8-fold ± 5.4-fold, respectively. On a percell basis, CACs harvested from G-CSF-mobilized blood displayed increased in vivo angiogenic potential compared with AMD3100-mobilized CACs. Mobilized EPCs displayed a greater proliferative capacity than EPCs isolated from baseline blood. Both CACs and EPCs were efficiently harvested by leukapheresis. Cryopreserved CACs but not EPCs retained functional activity after thawing. These data show that AMD3100 is a potent and rapid mobilizer of angiogenic cells and demonstrate the feasibility of obtaining and storing large numbers of angiogenic cells by leukapheresis.

AB - Circulating endothelial progenitor cells (EPCs) are thought to contribute to angiogenesis following vascular injury, stimulating interest in their ability to mediate therapeutic angiogenesis. However, the number of EPCs in the blood is low, limiting endogenous repair, and a method to rapidly mobilize EPCs has not been reported. In this study, healthy donors were mobilized sequentially with the CXCR4 antagonist, AMD3100, and G-CSF. The number of EPCs and circulating angiogenic cells (CACs) in the blood and pheresis product was determined and the angiogenic capacity of each cell population assessed. Compared with baseline, treatment with AMD3100 or G-CSF increased the number of blood CACs 10.0-fold ± 4.4-fold and 8.8-fold ± 3.7-fold, respectively. The number of EPCs in the blood increased 10.2-fold ± 3.3-fold and 21.8-fold ± 5.4-fold, respectively. On a percell basis, CACs harvested from G-CSF-mobilized blood displayed increased in vivo angiogenic potential compared with AMD3100-mobilized CACs. Mobilized EPCs displayed a greater proliferative capacity than EPCs isolated from baseline blood. Both CACs and EPCs were efficiently harvested by leukapheresis. Cryopreserved CACs but not EPCs retained functional activity after thawing. These data show that AMD3100 is a potent and rapid mobilizer of angiogenic cells and demonstrate the feasibility of obtaining and storing large numbers of angiogenic cells by leukapheresis.

UR - http://www.scopus.com/inward/record.url?scp=33749537886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749537886&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-06-030577

DO - 10.1182/blood-2006-06-030577

M3 - Article

C2 - 16912220

AN - SCOPUS:33749537886

VL - 108

SP - 3662

EP - 3667

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -